Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00913757 · ClinicalTrials.gov registry record
A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 1,871
- Enrollment target
NCT00913757: Completed study, sponsored by National Cancer Institute (NCI).
NCT00913757 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 1,871 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00913757 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 1,871 participants
- Enrollment target
Study Summary
Background: * Liver cancer is the third most deadly and fifth most common cancer worldwide. Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer, and it has grown more prevalent in the United States. * More information is needed about the causes and effects of liver cancer, and further research into individuals who are at high risk for developing liver cancer is needed for early diagnosis and prevention. Objectives: * To identify genetic factors that may help to explain the aggressiveness of liver cancer. * To determine if HCC biomarkers exist in blood, urine, and tissue samples. Eligibility: * Patients between the ages of 18 and 90 who have been diagnosed with HCC or have a high risk for developing HCC because of fatty liver disease (alcohol-related or non-alcohol-related) or chronic hepatitis B or C. * Participants will reside in Baltimore City and the surrounding areas. Design: * Participants will complete a questionnaire and provide blood and urine samples for testing: * The questionnaire will include questions about individual and family medical history, tobacco use, and exposure to known factors for liver cancer. * Blood and urine samples will be collected from all participants after the questionnaire. * Tumor tissue and healthy tissue will be collected from selected participants if they undergo surgery for their cancer or disease. * No specific treatment will be offered as part of this protocol, but participants have the option to be treated under different protocols.
Primary Outcome
Identification of HCC biomarkers for early diagnosis and prevention.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,871 participants |
| Start Date | 2009-07-01 |
| Est. Completion | 2020-05-01 |
What the finished NCT00913757 record still lists
NCT00913757 is an observational study that tracks outcomes without assigning an intervention. Its 1,871 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT00913757 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00913757 about?
NCT00913757 is a clinical study titled "A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area". Background: * Liver cancer is the third most deadly and fifth most common cancer worldwide. Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer, and it has grown more prevalent in the United States. * More information is needed about the causes and effects of liver cancer, and ...
What is the current status of trial NCT00913757?
This trial is currently completed. The enrollment target is 1,871 participants. The study started on 2009-07-01. Estimated completion is 2020-05-01.
Who is sponsoring clinical trial NCT00913757?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07203313 · 1,872 participants · NA
Evaluation of Aim to Play, a User-Friendly Digital Application for Teacher Skills Training and Physical Education Activities for 3-5 Grade Students
- NCT05675410 · 1,875 participants · Phase 3
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- NCT06891898 · 1,875 participants
The iLet Experience Study
- NCT07356089 · 1,875 participants
Twiist Postmarket Surveillance Study for Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI